MorphoSys Announces Clinical Milestone from Strategic Alliance
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Clinical Milestone from Strategic Alliance
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it
has received a milestone payment from Novartis in connection with the clinical
trial application (CTA/IND) and projected initiation of a phase 1 clinical
trial. The HuCAL-derived, fully human antibody will be developed in the
therapeutic area of cancer.
"Today's news marks the first clinical milestone for MorphoSys in 2012,"
commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "In
total, our collaboration with Novartis has resulted in six clinical programs to
date, with two being evaluated in phase 1 and four in phase 2. This excellent
progress clearly underpins the success of this collaboration. Our therapeutic
antibody pipeline continues to broaden and mature and is one of the broadest in
the industry."
MorphoSys's clinical pipeline now comprises twelve programs in phase 1 and nine
in phase 2 development including the Company's proprietary programs MOR103,
which is in a phase 1b/2a trial for rheumatoid arthritis and a phase 1b trial in
multiple sclerosis, MOR208, which is in a phase 1 trial for chronic lymphocytic
leukemia and MOR202, which is in a phase 1/2a trial for multiple myeloma.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), Ylanthia(®), CysDisplay(®),
RapMAT(®) and arYla(®) are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1597626/503607.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1597626]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Canamex CEO Greg Hahn Answers Questions About Its Aranka North Gold Exploration ProjectDatum: 28.03.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 129168
Anzahl Zeichen: 4554
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Clinical Milestone from Strategic Alliance"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
